AbbVie Announces European Commission Approval of AQUIPTA(R) (atogepant) for the Preventive Treatment of Migraine in Adults

AQUIPTA® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) approved for the prophylaxis of migraine in adults who have four or more migraine days per month ... Biopharmaceuticals, Neurology, Regulatory AbbVie, AQUIPTA, atogepant, migraine

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2048055

Source: HSMN NewsFeed - August 17, 2023 Category: Pharmaceuticals Source Type: news